Healthy Living

Rheumatoid Arthritis: Sirukumab Presents Safety Issues

Rheumatoid Arthritis: Sirukumab Presents Safety Issues

Rheumatoid Arthritis: Sirukumab Presents Safety Issues

In a report that was published on July 31st, 2017, the U.S. Food and Drug Administration (FDA) publicly stated the results of patients taking the rheumatoid arthritis (RA) drug, sirukumab, and patients taking a placebo. There were ultimately more fatalities in those patients who took sirukumab than of those who took the placebo. Johnson and Johnson, located in Irvine, California, is the creator of the experimental RA drug.